ANIX VS VTGN Stock Comparison

PerformanceAnalyst Price TargetsSentimentTechnicalsEarningsProfitVolatility
PerformanceAnalyst Price TargetsSentimentTechnicalsEarningsProfitVolatility

Performance

ANIX
10/100

ANIX returned -42.05% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

VTGN
10/100

VTGN returned -27.85% in the last 12 months. Based on SPY's performance of -13.95%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

ANIX
75/100

1 analysts offer 12-month price targets for ANIX. Together, they have an average target of 8, the most optimistic target put ANIX at 8 within 12-months and the most pessimistic has ANIX at 8.

VTGN
75/100

1 analysts offer 12-month price targets for VTGN. Together, they have an average target of 6, the most optimistic target put VTGN at 6 within 12-months and the most pessimistic has VTGN at 6.

Sentiment

ANIX
67/100

ANIX had a bullish sentiment score of 66.58% across Twitter and StockTwits over the last 12 months. It had an average of 1.57 posts, 0.29 comments, and 1.43 likes per day.

VTGN

"Sentiment" not found for VTGN

Technicals

ANIX
11/100

ANIX receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

VTGN
50/100

VTGN receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.

Earnings

ANIX
61/100

ANIX has missed earnings 3 times in the last 20 quarters.

VTGN
10/100

VTGN has missed earnings 10 times in the last 20 quarters.

Profit

ANIX
10/100

Out of the last 20 quarters, ANIX has had 0 profitable quarters and has increased their profits year over year on 0 of them.

VTGN
10/100

Out of the last 20 quarters, VTGN has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

ANIX
34/100

ANIX has had a lower than average amount of volatility over the last 12 months giving it a score of 34 of 100.

VTGN
42/100

VTGN has had a lower than average amount of volatility over the last 12 months giving it a score of 42 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Anixa Biosciences, Inc. Summary

Nasdaq / ANIX
Healthcare
Biotechnology
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Vistagen Therapeutics, Inc. Common Stock Summary

Nasdaq / VTGN
Healthcare
Biotechnology
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.